Biological Aging and Later Type 2 Diabetes in Fatty Liver Disease
Studies whether faster biological aging links to later diabetes in fatty liver.
Plain-language title generated from the registry record
Registry title: Accelerated Biological Aging is Associated With Increased Risk of T2DM in the MASLD Population
Key facts
- Where
- Ningbo, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
This study looks at adults who had a yearly health check-up with an abdominal ultrasound and some metabolic test results on record. It studies whether faster biological ageing is linked to type 2 diabetes.
- Age
- 20 to 90 years
- Sex
- All sexes can join.
- Disease stage
- Must not have type 2 diabetes at the start. The record does not name a liver disease stage.
- Biomarker or test result
- Abdominal ultrasound data are needed. At least one yearly metabolic measure is needed: BMI or waist size, blood pressure, triglycerides, HDL cholesterol, or fasting glucose or HbA1c.
Main reasons for not taking part
- Younger than 20 or older than 90 years
- Fatty liver from other causes, such as alcoholic liver disease or hepatitis B infection
- Type 2 diabetes at the start
- Missing baseline results for any of the listed blood tests and measures, such as blood pressure, albumin, creatinine, HbA1c, fasting glucose or white blood cell count
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 20 and 90 years old?
Source: NCT06984510, who can take part
Where in China
- the First Affiliated Hospital of Ningbo University Ningbo, Zhejiang, China, 315000Ningbo, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ningbo No. 1 Hospital
- Trial code
- NCT06984510
- Record updated
- 4 June 2025
- Original description
The association between biological aging and type 2 diabetes mellitus (T2DM) incidence in individuals with and without metabolic dysfunction-associated steatotic liver disease (MASLD) remains unclear.We assessed biological age by calculating phenotypic age (PhenoAge), Klemera-Doubal method (KDMAge), and homeostatic dysregulation (HDAge). To examine the association of biological ageing with the risk of T2DM, cox regression models were conducted. Furthermore, we applied survival analysis, restricted cubic spline models and population attributable fraction (PAF) to further evaluate the association between biological ageing and T2DM incidence.Read full original descriptionShow less
Accelerated Biological Aging is Associated With Increased Risk of T2DM in the MASLD Population: a Cohort Study
The association between biological aging and type 2 diabetes mellitus (T2DM) incidence in individuals with and without metabolic dysfunction-associated steatotic liver disease (MASLD) remains unclear.We assessed biological age by calculating phenotypic age (PhenoAge), Klemera-Doubal method (KDMAge), and homeostatic dysregulation (HDAge). To examine the association of biological ageing with the risk of T2DM, cox regression models were conducted. Furthermore, we applied survival analysis, restricted cubic spline models and population attributable fraction (PAF) to further evaluate the association between biological ageing and T2DM incidence.
Inclusion: Abdominal ultrasound data available in annual health check-up records; At least one of the following five metabolic indicators recorded annually:; (1) Body mass index (BMI) or waist circumference (2) Blood pressure (3) Serum triglycerides (4) High-density lipoprotein cholesterol (HDL-C) (5) Fasting plasma glucose or glycated hemoglobin (HbA1c).
Exclusion: Other causes of hepatic steatosis (e.g., alcoholic liver disease or hepatitis B infection); Type 2 diabetes mellitus at baseline; Missing baseline data for any of the following variables: systolic blood pressure, albumin, alkaline phosphatase, blood urea nitrogen, creatinine, glycated hemoglobin (HbA1c), total cholesterol, lymphocyte percentage, white blood cell count, mean corpuscular volume, uric acid, fasting plasma glucose, and red cell distribution width (RDW); Age <20 or >90 years.